The Netherlands is rapidly establishing itself as a key hub for biotech clinical trials, offering streamlined regulatory access, advanced digital infrastructure, and strong collaboration between academic centers and industry. These advantages make it especially attractive for high-innovation trials in oncology, rare diseases, and advanced therapies. In the article, Allucent experts Raymond Hoffmans and Lindsy Bosch share how CROs like Allucent provide the expertise and local knowledge biotechs need to overcome operational hurdles and accelerate trial success in Europe.
Read the full article at labiotech.eu to explore how the Netherlands can be your strategic gateway to Europe.
Raymond Hoffmans, PhD, Vice President, Corporate Services at Allucent
Raymond Hoffmans, PhD has more than 15 years’ professional experience in clinical research. In his current position as VP, Corporate Services at Allucent, he is responsible for implementing the strategic objectives of corporate services. Prior to this role, Raymond Hoffmans was Chief Business Development Officer at SMS-oncology and was instrumental in the continuous success and growth of SMS-oncology until he became head of integration management and successfully lead four integrations of the various companies that are now combined into Allucent.
Raymond Hoffmans holds a Ph.D. in natural science from the Molecular Biology Institute at the University of Zurich and was a postdoctoral research fellow at the Dana Farber Cancer Institute (Harvard Medical School) in Boston, as well as at the Hubrecht Institute in Utrecht.
Lindy Bosch, MSc (Biomedical Sciences), Senior Director, Business Development at Allucent
Lindy Bosch is an ambitious and passionate Business Development expert in the CRO/drug development industry, with over 11 years of industry experience. Starting in the joint position of a Clinical Trial Assistant and Business Developer, Lindy progressed into her current position of Senior Director, Business Development at Allucent. In her current role, Lindy is responsible for sales, acquisition and account management for biopharma companies in The Netherlands and the Nordics. She has a proven track record in achieving and exceeding sales targets, and is exceptionally skilled in networking, acquiring new clients, as well as building and fostering strong relationships.
Lindy holds a Master’s degree in Biomedical Sciences from the University of Groningen, combined with a Business & Policy Master’s Track.
Request a Proposal
Share This
